Prognostic impact of pretreatment cell‐free DNA concentration in newly diagnosed peripheral T‐cell lymphomas
Open Access
- 4 January 2024
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 204 (5) , 1752-1756
Abstract
Summary: Peripheral T‐cell lymphomas (PTCLs) have a poor prognosis and, to date, there are no reliable predictive biomarkers of response. In this work we explored the prognostic impact of cell‐free DNA (cfDNA) concentration in 75 newly diagnosed patients enrolled in a prospective multicenter study. Pre‐treatment cfDNA was strongly associated with clinical risk factors and was identified as a superior predictor for shorter progression‐free survival in multivariable analysis, outweighing canonical risk parameters. Furthermore, we identified a cfDNA value above which survival worsens. In conclusion, pre‐treatment cfDNA concentration represents an easily usable predictive biomarker that is highly associated with survival of PTCL patients.Keywords
Funding Information
- Associazione Italiana per la Ricerca sul Cancro (IG22089)
This publication has 8 references indexed in Scilit:
- Cell-Free DNA: Hope and Potential Application in CancerFrontiers in Cell and Developmental Biology, 2021
- Plasma cell-free DNA is a prognostic biomarker for survival in patients with aggressive non-Hodgkin lymphomasAnnals of Hematology, 2020
- Assessment of Cell-Free DNA (cfDNA) in 221 Patients with Lymphoproliferative Malignancies at Diagnosis and during Follow-upBlood, 2019
- The analysis of cell-free DNA concentrations and integrity in serum of initial and treated of lymphoma patientsClinical Biochemistry, 2019
- Noninvasive Molecular Monitoring in Multiple Myeloma Patients Using Cell-Free Tumor DNAThe Journal of Molecular Diagnostics, 2018
- How I treat the peripheral T-cell lymphomasBlood, 2014
- Circulating nucleic acids (CNAs) and cancer—A surveyBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2007
- Neoplastic Characteristics of the DNA Found in the Plasma of Cancer PatientsOncology, 1989